clinical trial · NCT06703398
A Study of GC101 TIL in Advanced Melanoma
Shanghai Juncell Therapeutics·phase2·recruiting·n = 98
MelanomaGC101 TILdacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
brief summary
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
started
Dec 20, 2024
primary completion
May 12, 2026
completion
Dec 20, 2027
last updated
Aug 5, 2026
detailed description
This study is to investigate the efficacy and safety of autologous tumor infiltrating lymphocyte (GC101 TIL) therapy versus investigator's choice of chemotherapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with cyclophosphamide and hydroxychloroquine.
official title
A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol